Neuravi, an Irish medical device company, recently announced that it has received a total of $15 million in financing from IPF Partners to help its cerebral thrombectomy device EmboTrap land in the US market. The device was approved for entry into the European market last year and the second generation of the product was released last month. EmboTrap's main competitors are Solitaire under Medtronic and Trevo ProVue under Stryker.

EmboTrap was approved for the treatment of acute ischemic stroke. The device is capable of treating a patient by removing normal blood flow from blood clots in the blood vessels of the brain. The funds will be used to recruit patients in the United States and conduct a clinical study called ARISE II.

The company said that if the product can quickly enter the US market, EmboTrap will bring considerable returns to the company. It is estimated that the current market for thrombus removal equipment in the United States is nearly $1 billion, and the scale of trial production will increase to $1.4 billion in 2014. And EmboTrap, Solitaire and Trevo are expected to lead the world in the future.

Neuravi also said that compared to Solitaire and Trevo, EmboTrap has significant advantages, such as the ability to completely remove blood clots, avoiding other safety problems caused by residual blood clots, and the device can restore blood flow to the blood vessels before the blood clots clear. Helps patients with treatment.

Roller Hook Tomato Plant Support

Roller Hook Tomato Plant Support,Tomato Trellis-trellising,Greenhouse Tomato Plant,Accessory Trellising Roller Hook

JIANGSU SKYPLAN GREENHOUSE TECHNOLOGY CO.,LTD , https://www.greenhousehydroponic.com